Scientists identify trigger and treatment for non-alcoholic fatty liver diseaseCreated by:
People suffering from NAFLD (non-alcoholic fatty liver disease) can develop into steatosis, which can progress to cirrhosis and increase risk of hepatocellular carcinoma. The management for NAFLD has been lifestyle change by reducing fat in diet and weight loss. A study, by Cincinnati Children's Hospital Medical Center in Ohio, published in the journal Cell Reports found that a protein - cdk4 whicb is found in high amounts in mice taking high fat diet contributes to the sequelae of hepatocellular development.
The study found that cdk4 inhibitors ( flavopiridol and PD-0332991) have been successful in halting and even reversing steatosis in mice that have NAFLD. The testing of cdk4 inhibitors have been approved by the FDA and in clinical trials for liver cancer, so clinical trials for NAFLD shouldbe initiated with these drugs soon.